Wells Fargo lowered the firm’s price target on Nevro to $13 from $14 and keeps an Equal Weight rating on the shares. The firm notes the company reported a Q1 revenue beat but maintained 2024 revenue guidance due to some revenue pull forward into Q1 from Q2, and raised its EBITDA guidance. Fast enrollment in the PDN-SENSORY study suggests results could come soon, adds Wells.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVRO: